Aller au contenu principal
Profil bibliographique

Francesca Matta

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

5Publications signalées
139Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

Multiple Sclerosis Research StudiesSARS-CoV-2 and COVID-19 ResearchRheumatoid Arthritis Research and TherapiesMultiple Myeloma Research and TreatmentsLong-Term Effects of COVID-19

Les publications récentes

Accès ouvert 2026 article OpenAlex

Impact of cladribine tablets on PROs in patients with MS: insights from the 1st interim analysis of the CLADFIT-MS study

Giovanna Borriello, Clara Grazia Chisari, Davide Maimone, Francesca Matta et autres

Background Cladribine tablets are an oral short-course disease-modifying therapy (DMT) approved for the treatment of highly active relapsing multiple sclerosis (MS). While their efficacy has been demonstrated in clinical trials, limited real-world evidence is available on their impact on patient-reported outcomes (PROs) …

it, ch (code pays fourni par la source)

1 citation Frontiers in Neurology
Accès ouvert 2025 article OpenAlex

Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MS

Shalom Haggiag, Luca Prosperini, Massimo Filippi, Maria A. Rocca et autres

Importance: Early treatment choice in relapsing-remitting multiple sclerosis (RRMS) is prognostically crucial, yet robust comparative data on cladribine vs sphingosine-1-phosphate receptor modulators (S1PRMs) in treatment-naive patients with RRMS are limited. Objective: To compare the clinical effectiveness of cladribine vs S1PRMs in treatment-naive …

it, us, sk (code pays fourni par la source)

5 citations JAMA Network Open
Accès ouvert 2025 article OpenAlex

Real-world effectiveness and safety of ofatumumab in relapsing-remitting multiple sclerosis: Insights from naïve and switch patients

Clara Grazia Chisari, Salvatore Lo Fermo, Salvatore Iacono, Giuseppe Rosario Schirò et autres

Ofatumumab (OFA), a fully human anti-CD20 monoclonal antibody, has shown promising efficacy in treating relapsing multiple sclerosis (RMS) by depleting B cells and reducing disease activity. This real-world, prospective, multicenter study evaluated the effectiveness and safety of OFA in treatment-naïve patients and …

it, us (code pays fourni par la source)

7 citations Neurotherapeutics
Accès ouvert 2021 article OpenAlex

COVID-19 Severity in Multiple Sclerosis

Maria Pia Sormani, Irene Schiavetti, Luca Carmisciano, Cinzia Cordioli et autres

Background and Objectives It is unclear how multiple sclerosis (MS) affects the severity of COVID-19. The aim of this study is to compare COVID-19–related outcomes collected in an Italian cohort of patients with MS with the outcomes expected in the age- and …

it (code pays fourni par la source)

74 citations Neurology Neuroimmunology & Neuroinflammation
Accès ouvert 2021 article OpenAlex

SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

Maria Pia Sormani, Irene Schiavetti, Doriana Landi, Luca Carmisciano et autres

Background: The MuSC-19 project is an Italian cohort study open to international partners that collects data on multiple sclerosis (MS) patients with COVID-19. During the second wave of the pandemic, serological tests became routinely available. Objective: To evaluate the seroprevalence of anti-SARS-CoV-2 …

it, br, tr (code pays fourni par la source)

52 citations Multiple Sclerosis Journal

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.